Oridonin / DNase I loaded semi-interpenetrating network hydrogel as well as preparation method and application thereof

Through the semi-interpenetrating network hydrogel loaded with chemotherapy drugs, the problem of oral mucosal ulcers and inflammation difficult to heal, rapid healing and wound protection are achieved, and effective treatment strategies are provided.

CN119015210APending Publication Date: 2024-11-26XINXIANG MEDICAL UNIV

Patent Information

Application Number
CN202310596468.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-25
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Chemotherapy drugs cause damage to the oral mucosa, leading to ulcers and inflammation. The existing treatment methods lack effective prevention and treatment methods, especially the difficult-to-heal wound recurrence problem is difficult to solve.

Method used

Develop a hydrogel loaded with lemongrasin/DNase I semi-interpenetrating network. The hydrogel formed by binary copolymers and ε-polylysine can orderly release drugs and enzymes, and has rapid gel formation. , sustained and controlled release characteristics are suitable for oral environments. First, the DNase I releases to relieve inflammation, and then releases the antibacterial drug lycopene.

Benefits of technology

It significantly accelerates the healing of oral ulcers, reduces inflammation and bacterial infections, provides wound protection, improves the therapeutic effect of oral mucosal inflammation after chemotherapy, provides a "inflammatory trapping net" recovery mechanism for difficult-to-heal wounds, and provides a theoretical basis and treatment strategy for clinical practice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015210A_ABST
    Figure CN119015210A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to oridonin / DNaseI loaded semi-interpenetrating network hydrogel as well as a preparation method and application thereof. The hydrogel comprises a hydrogel matrix and a medicine, the hydrogel matrix is obtained by dissolving a biopolymer in 11-56 parts of a hydroxyethyl starch solution and 78 parts of an epsilon-polylysine solution; the biopolymer is obtained by reacting 1-2 parts of maleic anhydride, 1-100 parts of N, N-dimethylacrylamide and an azo initiator in a solvent, the medicine comprises deoxyribonuclease I and / or oridonin, and the semi-interpenetrating network hydrogel is high in gelling rate, simple, convenient and rapid in preparation process, mild in condition and suitable for industrial production. The medicine and enzyme activity are well kept, and the medicine has the advantages of slow release and controlled release effects and the like, is used for oral mucositis repeatedly attacked after chemotherapy and has a remarkable effect on wound surfaces difficult to heal.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to a Rubescensine A / DNase I loaded semi-interpenetrating network hydrogel and a preparation method and application thereof. Background Art

[0002] Chemotherapy is one of the main treatments for malignant tumors. The anti-tumor mechanism of chemotherapy drugs is mainly to directly affect the DNA structure of tumor cells, interfere with the synthesis of DNA and RNA of tumor cells, damage the spindle to terminate mitosis, etc. Although chemotherapy drugs can effectively kill tumor cells through the above pathways, their effects lack specificity, can cause immunosuppression and systemic toxic side effects, and are very likely to accidentally injure normal tissues and cells. They are toxic and irritating to normal tissues, especially to normal tissues with vigorous proliferation, such as oral mucosa. The damage is large, which will block the oral epithelial cell cycle, making the mucosal epithelial cells unable to divide and proliferate, causing inflammation of the oral mucosa, and then develop into ulcers, forming difficult-to-heal wounds and showing periodic recurrence characteristics. According to literature reports, up to 80% of patients develop oral mucosal ulcers after receiving high-dose chemotherapy, and almost all patients receiving head and neck radiotherapy, as well as 20-40% of patients receiving conventional chemotherapy will experience this situation. The cause of the disease is complex and is related to infection, allergy, gastrointestinal disease, nutritional deficiency, emotional disorders, etc. There are obvious individual differences, and there is currently no ideal method to control its recurrence.

[0003] Oral mucosal ulcers cause abnormal oral pain, especially after talking, eating and other stimulations. It not only greatly affects the patient's language, eating and sleep, but also seriously affects the quality of life and even hinders further treatment. Chemotherapy drugs damage the patient's oral mucosal cells, promote inflammatory reactions in the oral cavity and oral soft tissues, and lead to oral ulcers. In addition, chemotherapy drugs will affect the body's immune function, promote gastrointestinal dysfunction, vitamin and nutrient loss, oral environment disorder, aggravate oral ulcers, and seriously affect the quality of life of chemotherapy patients. Compared with simple oral ulcers, oral mucositis after chemotherapy not only damages epithelial cells, but also damages the vascular wall and submucosal connective tissue, and the normal flora of the surrounding environment of oral mucosal inflammation is disordered. Therefore, oral mucositis after chemotherapy has the particularity of simple oral ulcers: 1) local defective tissue of oral mucositis; 2) continuous inflammation of mucosal tissue and microenvironment; 3) local and surrounding flora disorder; 4) abnormal immune function of the body.

[0004] At present, there is a lack of effective prevention and treatment methods for oral ulcers and mucosal damage caused by chemotherapy. The treatment principle is mainly to relieve symptoms and prevent complications, including nutritional support, pain control, prevention and treatment of secondary infections, etc. The hydrogel has a high water content inside, and its physical properties are similar to the extracellular matrix (ECM), which can well simulate the structure of tissues in the human body, so it can be widely used in tissue engineering repair materials. Hydrogel can play a barrier protection role for wounds that are continuously damaged and difficult to heal, provide a mild, moist and breathable environment for the wound, relieve pain, and inhibit bacteria to improve the wound microenvironment. In addition, the hydrogel local adhesive drug delivery system can adhere to the oral mucosa well, which is conducive to long-term release of drugs and can maintain a high concentration of substances locally. Oral mucosal adhesion drug delivery is convenient and easy to disperse in the treatment of oral mucosal lesions. On the other hand, as the mucosal lesions are repaired, the adhered hydrogel degrades and falls off naturally, preventing the undegraded hydrogel from adhering for a long time, hindering the improvement of the wound microenvironment or even adhering to the new tissue to cause secondary damage. A number of studies have been conducted by those skilled in the art on hydrogels for treating oral ulcers. For example, the invention patent CN112426403B discloses an oral ulcer gel and its preparation method and application. The oral ulcer gel uses a lipid liquid crystal nano-encapsulation technology with high biosafety to encapsulate common oral therapeutic drugs with a liquid crystal sustained-release system made of oleic acid glyceride compounds and lecithin, and is matched with a film-forming agent, an adhesive and a taste regulator, so that the entire gel system not only has good coagulation and adhesion, but also has a good drug sustained-release effect, and has high biosafety. The invention patent CN114983982A discloses a sustained-release oral ulcer hydrogel ulcer patch, which can accelerate the healing of oral ulcer wounds, has no toxic side effects, and will not cause bacterial resistance when used for a long time, and has obvious advantages over hormone drugs and immunostimulants. However, oral mucosal ulcers caused by chemotherapy drugs are different from conventional oral mucosal ulcers, so the requirements for the gel system for treating oral mucosal ulcers are also different.

[0005] During the research process, the inventor unexpectedly obtained a safe and effective hydrogel that is antibacterial, relieves and promotes the repair of oral mucosal wounds after chemotherapy. The preparation process is simple and quick. It not only has a high drug loading capacity, but also maintains the activity of drugs and enzymes. It has degradation characteristics suitable for the oral environment. Since oral saliva contains salivary amylase, which is a type of α-amylase and has the highest specificity for starch and its derivatives, it hydrolyzes hydroxyethyl starch in IPN and first releases DNase-I. As time goes on, the gel hydrolyzes and swells, and the drug ORI is released. Summary of the invention

[0006] The primary purpose of the present invention is to provide a semi-interpenetrating network hydrogel loaded with oridonuclease A / DNase I, wherein the hydrogel comprises a hydrogel matrix and a drug; the hydrogel matrix is ​​obtained by dissolving a binary copolymer in 11-56 parts of a hydroxyethyl starch solution and 78 parts of an ε-polylysine solution; the binary copolymer is obtained by reacting 1-2 parts of maleic anhydride, 1-100 parts of N,N-dimethylacrylamide and an azo initiator in a solvent, and the drug comprises deoxyribonuclease I and / or oridonuclease A.

[0007] Preferably, the solvent in the binary copolymer is 1,4-dioxane.

[0008] Preferably, the molar ratio of maleic anhydride to N,N-dimethylacrylamide in the binary copolymer is 1:50.

[0009] Preferably, the azo initiator in the binary copolymer is azobisisobutyronitrile.

[0010] The second object of the present invention is to provide a method for preparing the semi-interpenetrating network hydrogel, wherein the method comprises the following steps:

[0011] (1) Synthesis of binary copolymer PMD

[0012] Weigh maleic anhydride, N,N-dimethylacrylamide and azobisisobutyronitrile, add 1,4-dioxane and stir magnetically to dissolve, and react under an argon atmosphere; cool the reaction solution to room temperature, precipitate with petroleum ether, filter, purify, and vacuum dry to constant weight to obtain white solid PMD;

[0013] (2) Preparation of unloaded hydrogel IPN

[0014] Dissolve hydroxyethyl starch in water; dissolve ε-polylysine in deionized water and adjust the pH; mix the two solutions; prepare a solution of PMD obtained in step (1), and mix and stir the two solutions to prepare a hydrogel IPN;

[0015] (3) Preparation of drug-loaded hydrogel ORI / DNase I / IPN

[0016] Hydroxyethyl starch was dissolved in water and mixed with DNase-1 solution; ε-polylysine was dissolved in deionized water and mixed with ORI solution, and pH was adjusted; the two solutions were mixed and stirred with PMD aqueous solution to prepare drug-loaded hydrogel ORI / DNase I / IPN.

[0017] Preferably, the reaction temperature in step (1) is 75°C, the reaction time is 8h, and the vacuum drying temperature is 75°C.

[0018] Preferably, the pH in step (2) and step (3) is adjusted by sodium hydroxide solution, and the pH range is 8-9.

[0019] Preferably, the concentration of the PMD aqueous solution in step (2) and step (3) is 37%-55%.

[0020] Preferably, the concentration of the DNase-1 solution in step (3) is 0.2-1.0 mg / mL, and the concentration of the ORI solution is 0.10-0.40 mg / mL.

[0021] The beneficial effects of the present invention are as follows: (1) The present invention provides a semi-interpenetrating network hydrogel loaded with oridonin A / DNase I, wherein the semi-interpenetrating network hydrogel is formed by a binary copolymer (PMD)-ε-polylysine (PLL), loaded with oridonin A and deoxyribonuclease, and the formed semi-interpenetrating network hydrogel can release oridonin A and deoxyribonuclease in an orderly manner.

[0022] (2) The semi-IPN hydrogel of the present invention has a fast gelation rate, a simple and fast preparation process, mild conditions, and good drug and enzyme activity. It also has the advantages of sustained release and controlled release. It is used for oral mucositis that recurs after chemotherapy and has a significant effect on difficult-to-heal wounds.

[0023] (3) The semi-IPN hydrogel of the present invention can be obtained under different ratios and preparation process conditions. The preparation reaction gelation rate is fast, and the preparation process conditions are mild and simple, so the drug loss is small and the enzyme activity is well maintained. The ORI encapsulation rate of the semi-IPN hydrogel is 62-97%, and the drug loading is 1.4-5.6%; the DNase I encapsulation rate is 68-97%, and the drug loading is 1.1-5.4%. The oral ulcer healing speed of the semi-IPN hydrogel is the fastest, indicating that it can significantly accelerate the healing of oral ulcers.

[0024] (4) The hydroxyethyl starch in the semi-interpenetrating network hydrogel described in the present invention is first degraded under the action of oral salivary amylase and the released DNase I degrades the NETs of the mucosal inflammatory tissue, reduces the inflammatory effect and inflammatory damage of the wound microenvironment, improves the immune function, and then releases the antibacterial drug ORI to reduce the bacterial infection of the wound. The unhydrolyzed hydrogel part still serves as a wound covering to protect the wound and help the wound mucosal tissue heal.

[0025] (5) The present invention constructs oral mucositis in rats after chemotherapy to evaluate the therapeutic effect of hydrogel on oral mucosal inflammation, and uses oral ulcers after chemotherapy as a model of difficult-to-heal wounds to verify the "inflammatory trap" recovery mechanism of difficult-to-heal wounds, providing a theoretical basis and treatment strategy reference for clinical tumor patients with difficult-to-heal wounds such as ulcers caused by chemotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 Synthetic route of binary copolymer PMD and gel

[0027] Figure 2 Fourier infrared spectra of gel and raw materials

[0028] Figure 3 IPN macroscopic view and scanning electron microscope image

[0029] Figure 4 Degradation rate of IPN in PBS with different pH values

[0030] Note: Release solution A is PBS with α-amylase added, and release solution B is PBS

[0031] Figure 5 Hemolysis phenomenon and hemolysis rate of IPN hydrogel

[0032] Figure 6 Cell scratch test results and scratch closure rate statistics

[0033] Figure 7 Drug release curves of ORI / DNase I / IPN in release media with different pH values

[0034] Figure 8 Effect of hydrogel on cell viability

[0035] Fig. 9 Gel antibacterial effect

[0036] Fig.10 In vitro inhibition of NETs fluorescence microscopy and fluorescence intensity measurement effects

[0037] Fig.11 Body weight changes of mice in each drug group

[0038] Fig.12 HE staining of pathological sections of main organs of mice

[0039] Fig.13 Average daily food intake of rats

[0040] Fig.14 Repair of inflammatory tissue in rat oral mucosa

[0041] Note: A: Macroscopic observation of mucositis; B: Statistical analysis of wound closure area

[0042] Fig.15 HE staining of SD rat oral mucosal inflammation tissue sections.

[0043] Note: A. Healthy SD rats; B. Control; C. IPN; D. ORI / IPN; E. DNase-I / IPN; F. ORI / DNase-I / IPN Fig.16 Contents of TNF-α, IL-1β and IL-6 in inflammatory tissues of oral mucosa of rats

[0044] Fig.17 Degradation rate of semi-IPN hydrogel PMD-PAH-HES

[0045] Fig.18 Degradation rate of semi-IPN hydrogel PMD-HA-HES

[0046] Fig.19 Degradation rate of semi-IPN hydrogel PMD-PLL-CMC

[0047] Fig. 20 Stability of semi-IPN hydrogels

[0048] Fig.21 Adhesion of semi-IPN hydrogels DETAILED DESCRIPTION

[0049] The protection scope of the present invention is described in detail below in conjunction with specific embodiments. It should be noted that the protection scope of the present invention is not limited by the following embodiments.

[0050] Deoxyribonuclease (DNase-I) is an endonuclease that can digest single-stranded or double-stranded DNA and can degrade neutrophil extracellular traps (NETs). NETs are a unique ultrastructure composed of extracellular unwinding DNA, histones, and proteins with inflammatory and bactericidal activities. Studies have confirmed that DNase-I removes and inhibits NETs, ​​promotes skin wound healing, and reduces wound inflammatory response. Loading DNase-I into hydrogels and acting on NETs may achieve the advantages of improving drug pharmacokinetics, targeted delivery, and targeted drug release in response to the lesion microenvironment.

[0051] Oridonin (ORI) is a natural bioactive substance of the kauren-type tetracyclic diterpenoids isolated from the plant of the genus Isodonium of the family Lamiaceae. It has antibacterial, anti-inflammatory and analgesic effects and is clinically used as an adjuvant treatment for oral inflammation and cancer.

[0052] Hydroxyethyl starch is a polymer complex formed by hydroxyethylation of the glucose ring of amylopectin. It is a synthetic colloidal solution used clinically and is also a good natural material source for preparing hydrogels. Therefore, it has good safety and biocompatibility as a wound repair hydrogel material. Since oral saliva contains salivary amylase, which is a type of α-amylase, it has the highest specificity for starch and its derivatives and hydrolyzes hydroxyethyl starch in IPN. Therefore, the semi-interpenetrating network hydrogel originally designed and prepared by ε-polylysine and hydroxyethyl starch can play a barrier protection role for wounds with persistent mucosal damage and difficulty in healing, provide a mild, moist and breathable environment for the wound, relieve pain, inhibit bacteria and improve the wound microenvironment. More importantly, it can slowly degrade in the physiological environment of oral saliva, release drugs, and degrade and fall off after a certain period of action, which can protect the wound tissue in time and naturally fall off.

[0053] ε-Polylysine (ε-PLL) is a natural polypeptide antibacterial agent with the advantages of high water solubility, high thermal stability and low toxicity. It has significant inhibitory effects on fungi, Gram-negative bacteria and Gram-positive bacteria, so it is widely used in food preservation, drug delivery and other fields. The polylysine matrix gives the hydrogel excellent liquid absorption, moisture retention, adhesion and antibacterial properties, providing a moist, sterile, semi-enclosed microenvironment for the wound surface and promoting wound repair. For example, polylysine is prepared into a hydrogel for wound in situ photopolymerization, which has the characteristics of wound adaptability, good antibacterial ability, biocompatibility, and promotion of wound healing. The surface antibacterial ability against Staphylococcus aureus, Escherichia coli and Vibrio vulnificus is close to 100%.

[0054] In the following examples, SPSS19.0 statistical software was used for analysis, and the deviations of all data were expressed as mean ± standard deviation (x ± s). The t test was used to compare the data between two groups, and the least significant difference test was used to compare three groups or more. One-way analysis of variance was used, and the test level was a = 0.05. P < 0.05 was considered to be statistically significant.

[0055] Example 1. Preparation of semi-IPN hydrogel

[0056] 1. Preparation of semi-IPN hydrogel

[0057] (1) Synthesis of binary copolymer PMD

[0058] PMD was synthesized as follows: 0.3076 g of maleic anhydride, 15.55 g of N,N-dimethylacrylamide (amount ratio of 1:50) and 0.1314 g of azobisisobutyronitrile AIBN (1 / 200 of the total amount of substance concentration) were weighed, and then 160 mL of 1,4-dioxane was added and dissolved by magnetic stirring, and reacted at 75 ° C for 8 h under an argon atmosphere. The reaction solution was cooled to room temperature, precipitated with petroleum ether, filtered, purified, and vacuum dried at 70 ° C to constant weight to obtain white solid PMD.

[0059] (2) Preparation of unloaded hydrogel IPN

[0060] 0.05 g of hydroxyethyl starch was dissolved in 1 mL of water; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and adjusted to pH 8.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 37% PMD aqueous solution for 1 min to prepare a hydrogel IPN.

[0061] (3) Preparation of drug-loaded hydrogel ORI / DNase I / IPN

[0062] 0.05 g of hydroxyethyl starch was dissolved in 1 mL of water and mixed with 0.2 mL of 500 μg / mL DNase-1 solution; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and 0.5 mL of 200 μg / mL ORI solution, and the pH was adjusted to 8.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 37% PMD aqueous solution for 1 min to prepare the drug-loaded hydrogel ORI / DNase I / IPN.

[0063] 2. Preparation of Semi-IPN Hydrogel

[0064] (1) Synthesis of binary copolymer PMD

[0065] PMD was synthesized as follows: 0.3076 g of maleic anhydride, 15.55 g of N,N-dimethylacrylamide (amount ratio of 1:50) and 0.1314 g of azobisisobutyronitrile AIBN (1 / 200 of the total amount of substance concentration) were weighed, and then 160 mL of 1,4-dioxane was added and dissolved by magnetic stirring, and reacted at 75 ° C for 8 h under an argon atmosphere. The reaction solution was cooled to room temperature, precipitated with petroleum ether, filtered, purified, and vacuum dried at 70 ° C to constant weight to obtain white solid PMD.

[0066] (2) Preparation of unloaded hydrogel IPN

[0067] 0.02 g of hydroxyethyl starch was dissolved in 1 mL of water; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and adjusted to pH 9.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 37% PMD aqueous solution for 1 min to prepare a hydrogel IPN.

[0068] (3) Preparation of drug-loaded hydrogel ORI / DNase I / IPN

[0069] 0.02 g of hydroxyethyl starch was dissolved in 1 mL of water and mixed with 0.2 mL of 500 μg / mL DNase-1 solution; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and 0.5 mL of 200 μg / mL ORI solution, and the pH was adjusted to 9.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 37% PMD aqueous solution for 1 min to prepare the drug-loaded hydrogel ORI / DNase I / IPN.

[0070] 3. Preparation of Semi-IPN Hydrogel

[0071] (1) Synthesis of binary copolymer PMD

[0072] PMD was synthesized as follows: 0.3076 g of maleic anhydride, 15.55 g of N,N-dimethylacrylamide (amount ratio of 1:50) and 0.1314 g of azobisisobutyronitrile AIBN (1 / 200 of the total amount of substance concentration) were weighed, and then 160 mL of 1,4-dioxane was added and dissolved by magnetic stirring, and reacted at 75 ° C for 8 h under an argon atmosphere. The reaction solution was cooled to room temperature, precipitated with petroleum ether, filtered, purified, and vacuum dried at 70 ° C to constant weight to obtain white solid PMD.

[0073] (2) Preparation of unloaded hydrogel IPN

[0074] 0.10 g of hydroxyethyl starch was dissolved in 1 mL of water; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and adjusted to pH 8.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 55% PMD aqueous solution for 1 min to prepare a hydrogel IPN.

[0075] (3) Preparation of drug-loaded hydrogel ORI / DNase I / IPN

[0076] 0.10 g of hydroxyethyl starch was dissolved in 1 mL of water and mixed with 0.2 mL of 500 μg / mL DNase-1 solution; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and 0.5 mL of 200 μg / mL ORI solution, and the pH was adjusted to 8.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 55% PMD aqueous solution for 1 min to prepare the drug-loaded hydrogel ORI / DNase I / IPN.

[0077] 4. Preparation of Semi-IPN Hydrogel

[0078] (1) Synthesis of binary copolymer PMD

[0079] PMD was synthesized as follows: 0.3076 g of maleic anhydride, 15.55 g of N,N-dimethylacrylamide (amount ratio of 1:50) and 0.1314 g of azobisisobutyronitrile AIBN (1 / 200 of the total amount of substance concentration) were weighed, and then 160 mL of 1,4-dioxane was added and dissolved by magnetic stirring, and reacted at 75 ° C for 8 h under an argon atmosphere. The reaction solution was cooled to room temperature, precipitated with petroleum ether, filtered, purified, and vacuum dried at 70 ° C to constant weight to obtain white solid PMD.

[0080] (2) Preparation of unloaded hydrogel IPN

[0081] 0.05 g of hydroxyethyl starch was dissolved in 1 mL of water; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and adjusted to pH 8.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 55% PMD aqueous solution for 1 min to prepare a hydrogel IPN.

[0082] (3) Preparation of drug-loaded hydrogel ORI / DNase I / IPN

[0083] 0.05 g of hydroxyethyl starch was dissolved in 1 mL of water and mixed with 0.2 mL of 1000 μg / mL DNase-1 solution; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and 0.5 mL of 400 μg / mL ORI solution, and the pH was adjusted to 8.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 55% PMD aqueous solution for 1 min to prepare the drug-loaded hydrogel ORI / DNase I / IPN.

[0084] 5. Preparation of Semi-IPN Hydrogel

[0085] (1) Synthesis of binary copolymer PMD

[0086] PMD was synthesized as follows: 0.3076 g of maleic anhydride, 15.55 g of N,N-dimethylacrylamide (amount ratio of 1:50) and 0.1314 g of azobisisobutyronitrile AIBN (1 / 200 of the total amount of substance concentration) were weighed, and then 160 mL of 1,4-dioxane was added and dissolved by magnetic stirring, and reacted at 75 ° C for 8 h under an argon atmosphere. The reaction solution was cooled to room temperature, precipitated with petroleum ether, filtered, purified, and vacuum dried at 70 ° C to constant weight to obtain white solid PMD.

[0087] (2) Preparation of unloaded hydrogel IPN

[0088] 0.05 g of hydroxyethyl starch was dissolved in 1 mL of water; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and adjusted to pH 8.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 55% PMD aqueous solution for 1 min to prepare a hydrogel IPN.

[0089] (3) Preparation of drug-loaded hydrogel ORI / DNase I / IPN

[0090] 0.05 g of hydroxyethyl starch was dissolved in 1 mL of water and mixed with 0.2 mL of 200 μg / mL DNase-1 solution; an appropriate amount of ε-PLL was dissolved in 0.5 mL of deionized water and 0.5 mL of 100 μg / mL ORI solution, and the pH was adjusted to 8.0 with sodium hydroxide; the two solutions were mixed and stirred with 1 mL of 55% PMD aqueous solution for 1 min to prepare the drug-loaded hydrogel ORI / DNase I / IPN.

[0091] At the same time, according to the preparation method of the semi-IPN hydrogel 1 in Example 1, single drug hydrogels, namely, ORI-loaded hydrogel ORI / IPN and DNase I-loaded hydrogel DNase I / IPN, were prepared for comparative experiments. Example 2 Drug loading and release characteristics of semi-IPN hydrogels

[0092] 1. Experimental Procedure

[0093] HPLC analysis conditions of Rubescensine A:

[0094] Chromatography: Aligent 1260 high performance liquid chromatograph (G1311C quaternary pump, G1329B injector, G1316A column oven, G4212B DAD UV detector), workstation: Aligent Openlab CDS chemstation, chromatographic column: stainless steel column (Daisogel ID20mm x 150mm, 5μm), flow rate: 1mL / min, column temperature: 25℃, 20μL automatic injection. Mobile phase: methanol and water (48:52, v / v), flow rate 1.0mL / min; detection wavelength: 239nm.

[0095] The semi-IPN hydrogel prepared in Example 1 was placed in a test tube, and 2.0 ml of phosphate buffered saline (PBS, pH 6.8, 37°C) containing amylase (25 U / mg) was added. The mixture was shaken in an air bath shaker at (37±1)°C and (75±1) rpm. Four parallel samples were prepared for the release of each gel. All the release liquid was centrifuged at fixed time intervals, and an equal amount of fresh PBS containing type I collagenase was added. The release curve was plotted with the cumulative release rate as the ordinate and time as the abscissa.

[0096] 2. Experimental results

[0097] Table 1 Encapsulation efficiency and drug loading of semi-IPN hydrogels

[0098]

[0099] The encapsulation efficiency and drug loading of semi-IPN hydrogels 1, 2, 3, 4 and 5 are shown in Table 1. Changing the hydroxyethyl starch, the reaction pH value and the ratio of the input drugs did not significantly increase the encapsulation efficiency of the two drugs. For example, semi-IPN hydrogel 2, by reducing the amount of hydroxyethyl starch input, can still gel rapidly by adjusting the pH to 9.0, but the DNase I encapsulation efficiency is significantly reduced, indicating that the pH value of the gelling solution may affect the activity of DNase I, resulting in a decrease in the encapsulation efficiency and drug loss. Semi-IPN hydrogel 4, by increasing the dosage of the two drugs, the gel loading increased, but the encapsulation efficiency of both drugs decreased, indicating that the amount of drug loss increased, and the ORI solubility was close to saturation, increasing the drug pretreatment time. Due to the fast reaction gelation rate, the preparation process conditions are mild and simple, because the drug loss is small and the enzyme activity is well maintained.

[0100] The in vitro drug release behaviors of three semi-IPN hydrogels (1, 3 and 5) with no significant difference in encapsulation efficiency were further determined. Figure 1As shown, in the three release media of pH 6.0, pH 7.0 and pH 8.0, the release rate of DNase I of semi-IPN hydrogel 1 is greater than that of ORI, that is, DNase I is released first, followed by ORI. Since hydroxyethyl starch loads DNase I and α-amylase hydrolyzes hydroxyethyl starch, DNase I is released. As time goes on, the hydrogel formed by PLL and PMD degrades and ORI is released. This is consistent with the results of the previous IPN in vitro degradation experiment. The drug release rate is different in release media with different pH values. For example, at 48h, in the release media of pH 6.0, pH 7.0 and pH 8.0, the cumulative release of DNase I is 50.8%, 55.6% and 49.8%, respectively; and the release of ORI is 73.6%, 76.5% and 67.8%, respectively. At 72h, DNase I in the three release media has reached more than 80%; the cumulative release of ORI is 61.2%, 64.6% and 62.3%, respectively (as shown in Figure 2). Figure 1 A, B, and C show). Increasing the concentration of hydroxyethyl starch in the second layer of the semi-interpenetrating network hydrogel 3 can effectively delay the release rate of the drug, especially the release rate of DNase I. The release rate of DNase I and ORI has no significant difference in timing. (As shown in Figure 1 D) The in vitro release behavior of semi-IPN hydrogel 5 is shown in the figure. The release rates of the two drugs are significantly different. DNase I is released first, and ORI is released later. However, the drug loading is small and the cumulative drug release is low (as shown in Figure 2). Figure 1 E).

[0101] In the following examples, semi-IPN hydrogel 1 was used for research.

[0102] Example 3: Physical and chemical properties test of semi-IPN hydrogel 1

[0103] 1. Infrared spectrum of synthetic products

[0104] The infrared spectra of the raw material and the hydrogel freeze-dried samples were measured by the potassium bromide tablet method using a Fourier transform infrared spectrometer (Daojin IR Tracer-100d).

[0105] 2. Hydrogel morphology

[0106] The freeze-dried gel sample was placed on a metal sheet, and the IPN morphology was observed using a field emission scanning electron microscope.

[0107] 3. Results Analysis

[0108] Synthesis route of binary copolymer PMD and gel Figure 2As shown, maleic anhydride and N,N-dimethylacrylamide synthesize a binary copolymer PMD, which is cross-linked with PLL and hydroxyethyl starch to form IPN. The preparation process is simple, a transparent gel is generated in 1 minute, and the reaction environment is mild. The drug and DNase enzyme activities are well maintained, and the content is almost not lost.

[0109] Figure 3 This is the infrared spectrum of the semi-IPN hydrogel sample 1. In the infrared spectrum of PMD, a methyl peak (2933 cm -1 ), methyl group symmetric deformation peak (1402cm-1), CO group stretching vibration peak (1052cm -1 ), 1623cm -1 The peak at 3227cm is attributed to the C=O of the amide bond. -1 The broad peak near 1557 cm is attributed to the stretching vibration of NH. -1 The peak at 2878 cm is related to the bending vibration of NH. -1 The peak at 1657cm is the stretching vibration peak of methylene. -1 The stretching vibration peak of the amide bond C=O is 1248 cm -1 The CN stretching vibration peak is at 2918cm -1 The methyl stretching vibration peak appears at 1619 cm -1 The peak at 1402cm is due to the blue shift of C=O stretching vibration. -1 A symmetrical methyl deformation peak appeared at 1248 cm -1 A CN peak appears at , indicating that the semi-IPN hydrogel 1 has characteristic peaks of its raw materials.

[0110] The semi-IPN hydrogel 1 has a white transparent colloid appearance. After freeze-drying, SEM observation shows that the gel is porous and loose sponge-like, with a pore size between 40-120 nm. Figure 4 shown.

[0111] Example 4: In vitro degradation performance of semi-IPN hydrogel 1

[0112] 1. Experimental Procedure

[0113] The semi-interpenetrating network hydrogel 1 prepared in Example 1 was accurately weighed as W0, and 10 mL of release liquid was added to compare the degradation rates of the semi-interpenetrating network hydrogels in different pH environments. At the same time, in order to compare the effect of α-amylase on the degradation rate of the semi-interpenetrating network hydrogel 1, a certain activity unit (100U / L) of α-amylase solution was added to PBS. It was placed in an air bath oscillator at (37±1)°C and (75±1)rpm for timing reaction. Three parallel experiments were performed for each sample. After a fixed reaction time, one piece was taken out and rinsed three times with triple distilled water, each time for 10 minutes. Weigh W1 and calculate the degradation percentage according to the following formula.

[0114] D%=(W0-W1) / Wo×100%

[0115] 2. Experimental results

[0116] Aldehydic starch, one of the raw materials in semi-IPN hydrogel, is a starch derivative. α-amylase can efficiently and specifically degrade starch and its derivatives. To simulate the human oral saliva environment, PBS with α-amylase was added as the in vitro release solution. Human saliva is generally acidic, with a pH value of 6.6-7.1. The degradation rate of IPN in PBS with three different pH values ​​(pH 6.0, pH 7.0 and pH 8.0) was determined. The results are shown in Figure 5 A. In the pH 7.0 environment, IPN degrades fastest. For example, within 48 h, the mass degradation percentages of IPN at pH 6.0, pH 7.0 and pH 8.0 were 11.5%, 17.4% and 9.4%, respectively, which were significantly higher than those in the pH 8.0 and pH 6.0 environments.

[0117] In the three PBS release solutions with different pH values ​​without α-amylase, the degradation rates of IPN were as follows: Figure 5 As shown in Figure B, there is no significant difference in degradation rate. In the same pH environment, the degradation rate in the release medium with amylase added is greater than that in the release medium without amylase added. For example, at 120 h, the release medium with pH 7.0 added with amylase degraded by 31.2%, while the release medium without amylase degraded by 19.3%.

[0118] Example 5. Hemolysis rate of semi-IPN hydrogel 1

[0119] 1. Experimental Procedure

[0120] 6mL of fresh blood from KM mice was extracted, anticoagulated with heparin, stirred with a glass rod to remove fibrinogen, then added with 4℃ precooled physiological saline, mixed, centrifuged at 1500rpm for 10min, discarded the supernatant, and washed repeatedly 2-3 times until the supernatant no longer showed red. The collected red blood cells were prepared into a 2% (w / v) red blood cell suspension with 4℃ precooled physiological saline, added to sterile centrifuge tubes, mixed, incubated in a 37℃ water bath incubator for 30min, and then added to the corresponding centrifuge tubes according to the table below. Incubate in a 37℃ water bath incubator for another 3h, observe every 30min, if brown-red floccules appear in the solution, it indicates that red blood cells are aggregated, then centrifuged at 1500rpm for 10min, take 100μL of supernatant, add to a 96-well plate, and detect the absorbance value at a wavelength of 540nm with an enzyme marker. Process the data and calculate the hemolysis rate according to the following formula.

[0121] Hemolysis rate (%) = (experimental group - negative control group) / (positive control group - negative control group) × 100%

[0122] 2. Experimental results

[0123] Compared with the positive control group, the hydrogel supernatant was colorless and transparent, with no hemolysis. Figure 6 As shown, according to the International Organization for Standardization 10993-4, a hemolysis rate of less than 5% is considered to have good blood compatibility. Therefore, the hydrogel meets the requirements of wound dressings and has good blood compatibility.

[0124] Example 6: Scratch test

[0125] 1. Experimental Procedure

[0126] The cells (L929 cells and HUVEC cells) attached to the 6-well culture plate were streaked in the 6-well plate with a 10μL sterile pipette tip; the cells were rinsed 2-3 times with PBS buffer to remove the suspended cells; then DMEM medium containing 5% fetal bovine serum was added and cultured. Taking the scratch time as the starting point, the cell growth state and the scratch healing were observed under an inverted microscope at 0, 24, 48 and 72 hours, and the cell pictures of each group were taken. The cell migration closure rate was evaluated by measuring the change in the distance between the scratches.

[0127] 2. Experimental results

[0128] The results of cell scratch assay are as follows Figure 7 As shown, there was no significant difference in the migration movement and closure rate of the two cells between the IPN group and the blank control group at 0, 24, 48 and 72 hours of treatment, indicating that the hydrogel IPN had no significant effect on the cell migration of L929 and HUVEC.

[0129] Example 7: Hydrogel Cytotoxicity

[0130] 1. Experimental Procedure

[0131] The MTT method was used to detect the cytotoxicity of the hydrogel to umbilical vein endothelial cells (HUVEC) and fibroblasts (L929). The sterilized hydrogel was immersed in DMEM for 24 hours to prepare the extract. The two types were inoculated in 96-well plates (1×10 4 cells), and cultured with the extract in a cell culture incubator at a CO2 volume fraction of 5% and a temperature of 37°C for 24 hours. PBS and cells were co-cultured as a control group. The absorbance value of the MTT-stained cell suspension at 450 nm was measured using an enzyme marker.

[0132] 2. Experimental results

[0133] The MTT assay was used to detect the cytotoxicity of the hydrogels on umbilical vein endothelial cells (HUVEC) and fibroblasts (L929). The cell survival rate was Figure 8 As shown in the figure, the cell survival rates of the non-drug-loaded IPN hydrogels were all greater than 90%. At the maximum concentration of 1000 μg / mL, the cell survival rates of the three groups of drug-loaded hydrogels were also greater than 80%.

[0134] Example 8: Antibacterial experiment of hydrogel

[0135] 1. Experimental Procedure

[0136] The cells were divided into five groups and given corresponding treatments (control group, IPN group, ORI / IPN group, DNase / IPN group and ORI / DNase / IPN group), and co-cultured with Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) in the culture medium for 3 h or 6 h, and then graded diluted, 20 μL of the diluted bacterial suspension was spread on the agar plate, and the agar plate was placed in a biochemical incubator for 24 h; finally, the inhibition rate was calculated according to the number of colonies on the plate, and the calculation formula is as follows:

[0137] Inhibition rate % = [(blank bacterial solution absorbance value - sample bacterial solution absorbance value) × 100 / blank bacterial solution absorbance value] %

[0138] 2. Experimental results

[0139] The results of antibacterial experiments are as follows Fig. 9As shown, due to the presence of a large number of conditional pathogens in the oral cavity, infection can be caused when antibiotics are used irrationally or leukopenia occurs after chemotherapy. The cultured bacterial solution was evenly divided into other liquid culture media, and then the set drugs and gel groups were added respectively, and incubated for 3h and 6h. The results showed that for Staphylococcus aureus (S. aureus), the ORI / IPN group, the DNase / IPN group and the ORI / DNase / IPN group had significant antibacterial effects. The antibacterial rate of the ORI / DNase / IPN group after incubation for 6h was significantly higher than that after incubation for 3h, reaching 86.7% at 6h, indicating that the antibacterial effect of the gel sustained-release drug increased with the extension of time; while this effect was not significant in the ORI / IPN group and the DNase / IPN group. For Escherichia coli (E. coli), the ORI / IPN group, the DNase / IPN group and the ORI / DNase / IPN group also showed significant antibacterial effects, and the antibacterial effect at 6h was significantly higher than that at 3h.

[0140] Example 9: Inhibition of NETs

[0141] 1. Experimental Procedure

[0142] Take the mouse bone marrow neutrophils, add 50μL of lipopolysaccharide (LPS) at a concentration of 2μg / mL to the stabilized cells, place them in an incubator for 4h to induce NETs, ​​then add Sytox green (green cyanine dye) to the cells, incubate in an incubator for 15min, and perform fluorescent staining on NETs. Remove the original culture medium and add phenol red-free culture medium to the well plate. Under a fluorescence microscope, excite green fluorescence and observe irregular reticular structures, which are NETs.

[0143] The mice were divided into five groups and given corresponding treatments (control group, IPN group, ORI / IPN group, DNase / IPN group and ORI / DNase / IPN group). After 30 minutes, green fluorescence was excited under a microscope, and the effect of the drug on NETs was quantified by fluorescence intensity (microplate reader). The changes of NETs were observed under a microscope and recorded by photographs.

[0144] 2. Experimental results

[0145] After LPS induction and fluorescence staining, neutrophils can be observed to present a reticular structure, namely NETs. The fluorescence intensity of NETs in the control group increased, indicating that the formation of NETs increased. After the gel extracts of each group were added for 30 minutes, it can be seen that NETs were significantly reduced, especially in the / DNase-I / IPN group and the ORI / DNase-I / IPN group. Compared with the control group, the fluorescence intensity was significantly different. This shows that it has a significant effect on degrading NETs. Specifically, Fig.10 shown.

[0146] Example 10: In vivo acute toxicity experiment

[0147] 1. Experimental Procedure

[0148] Thirty-six KM mice were selected, half male and half female, with a body weight of 16-18g. They were raised in the experimental environment for 2 days before the experiment, fasted 12h before the experiment, and had free access to water. They were randomly divided into 5 groups: control group, IPN group, ORI / IPN group, DNase / IPN group and ORI / DNase / IPN group. The mice were injected into the tail vein at a dose of 0.2mL / 10g (extract concentration was 1mg / mL). After one dose, they were observed for 4h continuously, and then observed once a day for 14 days. The poisoning symptoms and deaths were recorded. The limb characteristics, behavioral performance, food intake and feces of the mice were observed. The body weight and feed quality of the mice were weighed regularly, and the body weight and food intake of the mice in each group were statistically analyzed. Blood was collected before the mice were killed to test red blood cells (RBC), white blood cells (WBC), platelets (PLT), and hemoglobin (Hb); serum was separated and the automatic biochemical analyzer was used to test aspartate transferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and blood creatinine (Cr) to evaluate liver and kidney function. The mice were dissected to observe the changes in the main organs, and paraffin-embedded sections of the heart, liver, spleen, lung, and kidney were made, stained with HE, and observed under a microscope.

[0149] 2. Experimental results

[0150] The mice's stool, urine, color, fur, skin color, and breathing were all normal. There was no abnormal secretion from the nose, eyes, and mouth, no incontinence of stool or urine, and no abnormal phenomena such as bleeding and edema of the epidermis and mucous membranes. Immediately after the tail vein injection, the mice's activity decreased. After 10 minutes, the mice's activity gradually increased, their expressions gradually returned to normal, their appetite did not decrease significantly, and their weight gain was normal ( Fig.11 There were no obvious abnormalities in the behavior, fur, skin, breathing, defecation, etc. of the mice, and all mice survived at 14 days.

[0151] There were no significant differences in red blood cells, hemoglobin, platelets, white blood cells and their classification between the gel groups and the control group (Table 1). There were no significant differences in creatinine, urea nitrogen, alanine aminotransferase and aspartate aminotransferase between the treatment group and the control group. It was confirmed that the hydrogels in each group did not cause obvious liver and kidney toxicity.

[0152] Table 1 Hematological and blood biochemical parameters of mice

[0153]

[0154] No abnormal changes were observed on the surface and cross-section of the organs of each group of mice during the administration period and the recovery period. The animals were killed on the 14th day and the main organs were taken for pathological section HE staining and observation under a microscope (such as Fig.12 As shown in the figure, the myocardial fibers of each group were arranged neatly without degeneration and necrosis, the renal tubular structure of the kidney tissue was intact, the liver had no nodules and other tissue lesions, the spleen tissue structure was clear, the splenic nodule structure was normal, and no alveolar expansion or fusion was found in the lung tissue. Compared with the control group, no obvious pathological changes were found in various organs.

[0155] Example 11. Therapeutic effect of oral mucositis model in rats after chemotherapy

[0156] 1. Experimental Procedure

[0157] SPF grade 6-8 week old SD rats, half male and half female, weighing 180-220 g. Establishment of oral mucositis model Before modeling, 5 female and 5 male rats were randomly selected, a total of 10 rats, and housed in separate cages as the normal group.

[0158] Establishment of oral ulcer model induced by chemotherapy drugs (paclitaxel) in rats: Each model group was injected with chemotherapy drugs of corresponding concentration into the right buccal mucosa of rats, and the injection volume was 50μL / rat. The control group was injected with normal saline, and each group of animals was injected once on the day of modeling. After modeling, they were fasted for 24 hours. On the second day of modeling, obvious ulcer surface was seen in the oral mucosa, which was manifested as a white depression in the center of the ulcer, red and swollen edges, and signs of suppuration on the surface. The shape was basically a regular circle. Five groups were given treatment (control group, IPN treatment group, ORI / IPN treatment group, DNase / IPN treatment group and ORI / DNase / IPN treatment group), and the drug was given once every other day (i.e., 1st, 3rd and 5th day), and the gel treatment was given 3 times in total, and observed continuously for 7 days.

[0159] Determination of TNF-α, IL-1β, and IL-6 content in local tissues of rat oral mucositis: Ulcer tissue mucosa was cut from each group, and normal mucosa was cut from the normal group. The tissue was rinsed with pre-cooled saline to remove residual blood. The mucosa was cut into pieces and placed in a centrifuge tube, weighed, and then NP-40 lysis solution was added. The mucosa was fully crushed with a cell ultrafine grinder. The crushed tissue homogenate was placed in a high-speed centrifuge at 4°C and 5000rpm for 20 minutes, and the supernatant was removed with a pipette and stored in a -80°C refrigerator for later use. The TNF-α, IL-1β, and IL-6 content in the supernatant was determined according to the instructions of the ELISA kit.

[0160] Observe the ulcers with the naked eye, observe and record the ulcer formation, including the ulcer shape and area size, observe and record the ulcer healing condition and healing time.

[0161] Observation from mucosal tissue HE staining: Three rats were randomly selected from each group on the 3rd and 7th days after the model was successfully established, and the mucosal specimens were obtained. The mucosal specimens were rinsed with physiological saline and immediately placed in 4% paraformaldehyde solution for fixation. The tissues were embedded in paraffin, sliced ​​into 4μm sections, stained with HE, and then observed and analyzed under an optical microscope.

[0162] 2. Experimental results

[0163] The average daily food intake of each group Fig.13 As shown, on the first day, due to the early stage of ulceration, the food intake of each group was low, and there was no significant difference between the groups. The mucosal inflammation of the control group was not relieved, and the average daily food intake was less than that of the other groups. The food intake of the other four gel groups gradually increased from the 2nd to the 7th day, which was basically consistent with the result that the mucosal inflammation gradually recovered.

[0164] After the rat oral mucositis was established, the mucosa in the modeling area was edematous and a yellow-white pseudomembrane was formed. Fig.14 As shown in the figure, all treatment groups showed obvious healing on the 7th day, especially in the ORI / DNase 1 / IPN group, where the swelling basically disappeared on the 3rd day, and the surrounding tissue congestion disappeared. According to the statistics of the unclosed wound area in the experiment, it can be seen that the wound of the control group increased on the 5th day, and the wound closure area of ​​the ORI / DNase 1 / IPN group was about 76.3% on the 5th day. The results showed that the oral ulcer healing speed in the ORI / DNase 1 / IPN group was the fastest, indicating that the treatment can significantly accelerate the healing of oral ulcers; followed by the ORI / IPN group, indicating that the hydrogel composite ORI has a certain promoting effect on the healing of oral ulcers, and DNase 1 / IPN also accelerates the healing of ulcers relative to the IPN group; the control group did not show healing on the 7th day, showing inflammatory conditions such as mucosal suppuration.

[0165] Oral mucosa of healthy SD rats, such as Fig.15As shown in Figure A, it can be clearly divided into three layers from right to left: the first layer is the mucosal layer covered with keratinized stratified squamous epithelial cells; the second layer is the lamina propria, also known as the middle layer of the tympanic membrane, which is a dense and orderly connective tissue; and the last is the submucosal layer. The layers of cells in each part of the tissue are clear and closely dependent. After oral mucositis occurs, the various tissues of the oral mucosa show different degrees of damage depending on the degree. Figure B shows the HE staining of the oral mucosa of SD rats with oral ulcers after chemotherapy. It can be clearly seen that there are multiple inflammatory clusters in the mucosal layer (the part circled by the red oval), which lose the boundary with the lamina propria, and the inflammation penetrates into the lamina propria (the part circled by the red oval). The deep lamina propria and the part adjacent to the submucosal layer show disordered and irregular damage. Compared with the control group, after treatment with semi-IPN hydrogel IPN, the degree of inflammation was significantly reduced, and the mucosal layer and the lamina propria still maintained a boundary, but the density of the lamina propria cells decreased, and local inflammation invaded (Figure C, the part circled by the red ellipse), resulting in longitudinal damage to a small part of the lamina propria; after treatment with ORI / IPN, the mucosal layer was severely damaged (as shown in Figure D, there was no obvious large area of ​​mucosal layer), and the lamina propria only showed inflammatory aggregate damage on the surface (circled by the red ellipse); DNase-I / IPN treatment had a better effect, as can be seen from Figure E, The cells of the lamina propria were loose, and there was still inflammatory infiltration deep inside. The cells of the mucosal layer could not be arranged in a coherent manner, but the mucosal layer, lamina propria and submucosal layer could be basically distinguished normally. The drug-loaded semi-interpenetrating hydrogel ORI / DNase-I / IPN had excellent effect in treating oral ulcers. It can be seen from the HE color image F that the boundaries between the layers were clear. Compared with the healthy mucosa, the mucosal layer had only a small amount of inflammatory infiltration, and its cell distribution was not uniform. However, the lamina propria was dense and orderly, no different from healthy tissue, indicating that the ulcer surface basically recovered to normal levels after 7 days of ORI / DNase-I / IPN treatment.

[0166] The expression levels of TNF-α, IL-1β, and IL-6 in the local tissues of rat oral mucosal inflammation were determined, and the correlation between their expression levels and the development and repair effect of oral mucosal inflammation was analyzed. The results showed that ( Fig.16 ), the expression levels in local tissues at 7 days were lower than those at 3 days; especially in the ORI / DNase-I / IPN group, the expression levels of TNF-α, IL-1β, and IL-6 were significantly lower than those in other groups at 7 days (P<0.05), which was consistent with the results of mucosal inflammation repair.

[0167] Comparative Example 1: Semi-interpenetrating network hydrogel: binary copolymer (PMD)-polyacrylamine hydrochloride (PAH)-hydroxyethyl starch (HES) semi-interpenetrating network hydrogel (PMD-PAH-HES)

[0168] 1. Weigh 0.18-0.30 g of binary copolymer into a 10 mL test tube, add 1 mL of deionized water to dissolve (stir for 1 min) to obtain a binary copolymer aqueous solution;

[0169] Dissolve 0.037 g of poly(propyleneamine hydrochloride) in 2.1 mL of deionized water, then add an appropriate amount of 1 mol / L sodium hydroxide and stir evenly to adjust to alkalinity;

[0170] 3. Pour the solution in step 2 into the binary copolymer solution and mix well to form PMD-PAH-HES.

[0171] Comparative Example 2: Semi-interpenetrating network hydrogel: binary copolymer (PMD)-sodium hyaluronate (HA)-hydroxyethyl starch (HES) semi-interpenetrating network hydrogel (PMD-HA-HES)

[0172] 1. Weigh 0.18-0.30 g of binary copolymer into a 10 mL test tube, add 1 mL of deionized water to dissolve (stir for 1 min) to obtain a binary copolymer aqueous solution;

[0173] Dissolve 0.06 g of sodium hyaluronate in 2.1 mL of deionized water;

[0174] 3. Pour the solution from step 2 into the binary copolymer solution and mix well to form PMD-HA-HES gel.

[0175] Comparative Example 3: Semi-interpenetrating network hydrogel: binary copolymer (PMD)-ε-polylysine (PLL)-sodium carboxymethyl cellulose (CMC) semi-interpenetrating network hydrogel (PMD-PLL-CMC)

[0176] 1. Weigh 0.20-0.37 g of binary copolymer into a test tube, add 0.8 mL of deionized water to dissolve, and obtain binary copolymer aqueous solution A;

[0177] 2. Dissolve 0.03 g of ε-polylysine in 0.2 mL of deionized water, then add about 0.15 mL of sodium hydroxide solution (1 moL / L) and stir evenly to adjust to alkalinity.

[0178] 3. Add the binary copolymer aqueous solution to 1g of 4% sodium carboxymethyl cellulose solution, stir evenly, then pour the alkaline ε-polylysine solution into the system, stir evenly to form PMD-PLL-CMC gel.

[0179] Comparison of in vitro degradation performance

[0180] Based on the degradation performance comparison of the physiological environment of the oral cavity, IPN, PMD-PAH-HES and PMD-HA-HES hydrogels can be degraded in the environment containing amylase to simulate oral saliva, and the degradation rates are different in the three pH environments, which also shows that the three hydrogels containing starch and its derivatives have a fast degradation rate under the action of amylase ( Fig.17 , Fig.18 ). However, the degradation rate of PMD-PLL-CMC in the three pH environments had no significant difference, and the degradation rate was significantly lower than that of the other three hydrogels ( Fig.19 ).

[0181] Stability comparison

[0182] In order to evaluate the stability of the hydrogel, the hydrogel was placed in a physiological saline solution and placed in an oscillator (placed in an air bath oscillator at (37±1)℃ and (75±1)rpm for timing. Three parallel experiments were performed for each sample. The integrity of the hydrogel and the surface adhesion state were observed regularly. The IPN absorbed water and swelled in the physiological saline solution, remained intact after 48 hours, and broke after 72 hours. Comparison of hydrogels 1 and 2. At 24 hours, the fragmentation was observed by the naked eye, especially at 72 hours, when it had formed a large number of flocculent precipitates under the shaking conditions of the physiological saline solution, such as Fig. 20 shown.

[0183] The hydrogel was further observed to adhere to the surface of the glass slide and the surface of the rat mucosal tissue, and was placed in an oscillator (set at (37±1)℃, (75±1)rpm. The results showed that only IPN remained completely adhered to the surface of the glass slide and the surface of the rat mucosal tissue at 24h, 48h and 72h ( Fig.21 ), while the comparison hydrogels 1 and 2 fell off at 24 hours. When the hydrogel was further applied to the sublingual mucosal wound of the rat oral cavity, the hydrogel could fit tightly, maintain an intact appearance, and not fall off when the oral tongue was active and moist. This shows that IPN can adapt to the physiological environment of oral mucosal drug delivery.

[0184] In summary, the present invention provides a semi-interpenetrating network hydrogel loaded with oridonin / DNase I, wherein the semi-interpenetrating network hydrogel is formed by a binary copolymer (PMD)-ε-polylysine (PLL), loaded with oridonin and deoxyribonuclease, and the formed semi-interpenetrating network hydrogel can orderly release oridonin and deoxyribonuclease. The semi-interpenetrating network hydrogel of the present invention has a fast gelation rate, a simple and fast preparation process, mild conditions, and good drug and enzyme activity. It also has the advantages of sustained release and controlled release effects, and is used for oral mucositis that recurs after chemotherapy, and has a significant effect on difficult-to-heal wounds. The semi-interpenetrating network hydrogel of the present invention can be obtained under different ratios and preparation process conditions. The preparation reaction has a fast gelation rate, and the preparation process conditions are mild and simple, so the drug loss is small, and the enzyme activity is well maintained. The ORI encapsulation rate of the semi-IPN hydrogel is 62-97%, and the drug loading is 1.4-5.6%; the DNase I encapsulation rate is 68-97%, and the drug loading is 1.1-5.4%. The oral ulcer healing speed of the semi-IPN hydrogel is the fastest, indicating that it can significantly accelerate the healing of oral ulcers. The hydroxyethyl starch in the semi-IPN hydrogel of the present invention is first degraded under the action of oral salivary amylase, and the released DNase I degrades the NETs of the mucosal inflammatory tissue, reduces the inflammatory effect and inflammatory damage of the wound microenvironment, improves the immune function, and then releases the antibacterial drug ORI to reduce bacterial infection of the wound. The unhydrolyzed hydrogel part still serves as a wound cover to protect the wound and help the wound mucosal tissue heal. The present invention constructs oral mucositis in rats after chemotherapy to evaluate the therapeutic effect of hydrogel on oral mucosal inflammation, and uses oral ulcers after chemotherapy as a model of difficult-to-heal wounds to verify the "inflammatory trapping net" recovery mechanism of difficult-to-heal wounds, providing a theoretical basis and treatment strategy reference for difficult-to-heal wounds such as ulcers caused by chemotherapy in clinical tumor patients.

Claims

1. A semi-interpenetrating network hydrogel loaded with Rubescensine A / DNaseI, characterized in that: The hydrogel comprises a hydrogel matrix and a drug; the hydrogel matrix is ​​obtained by dissolving a binary copolymer in 11 to 56 parts of a hydroxyethyl starch solution and 78 parts of an ε-polylysine solution; the binary copolymer is obtained by reacting 1 to 2 parts of maleic anhydride, 1 to 100 parts of N, N-dimethylacrylamide and an azo initiator in a solvent, and the drug comprises deoxyribonuclease I and / or Rubescensine A.

2. The semi-interpenetrating network hydrogel according to claim 1, characterized in that: The solvent in the binary copolymer is 1,4-dioxane.

3. The semi-interpenetrating network hydrogel according to claim 1, characterized in that: The molar ratio of maleic anhydride to N,N-dimethylacrylamide in the binary copolymer is 1:

50.

4. The semi-interpenetrating network hydrogel according to claim 1, characterized in that: The azo initiator in the binary copolymer is azobisisobutyronitrile.

5. The method for preparing a semi-interpenetrating network hydrogel according to claim 1, characterized in that: The method comprises the following steps: (1) Synthesis of binary copolymer PMD Weigh maleic anhydride, N,N-dimethylacrylamide and azobisisobutyronitrile, add 1,4-dioxane and stir magnetically to dissolve, and react under an argon atmosphere; cool the reaction solution to room temperature, precipitate with petroleum ether, filter, purify, and vacuum dry to constant weight to obtain white solid PMD; (2) Preparation of unloaded hydrogel IPN Dissolve hydroxyethyl starch in water; dissolve ε-polylysine in deionized water and adjust the pH; mix the two solutions; prepare a solution of PMD obtained in step (1), and mix and stir the two solutions to prepare a hydrogel IPN; (3) Preparation of drug-loaded hydrogel ORI / DNaseI / IPN Dissolve hydroxyethyl starch in water and mix with DNase-1 solution; ε-Poly-lysine was dissolved in deionized water and mixed with the ORI solution, and the pH was adjusted; the two solutions were mixed and stirred with the PMD aqueous solution to prepare the drug-loaded hydrogel ORI / DNaseI / IPN.

6. The method for preparing a semi-interpenetrating network hydrogel according to claim 4, characterized in that: The reaction temperature in step (1) is 75°C, the reaction time is 8h, and the vacuum drying temperature is 75°C.

7. The method for preparing a semi-interpenetrating network hydrogel according to claim 4, characterized in that: The pH in step (2) and step (3) is adjusted by sodium hydroxide solution, and the pH range is 8-9.

8. The method for preparing a semi-interpenetrating network hydrogel according to claim 4, characterized in that: The concentration of the PMD aqueous solution in step (2) and step (3) is 37%-55%.

9. The method for preparing a semi-interpenetrating network hydrogel according to claim 4, characterized in that: The concentration of the DNase-1 solution in step (3) is 0.2-1.0 mg / mL, and the concentration of the ORI solution is 0.10-0.40 mg / mL.

Citation Information

Patent Citations

  • An oral ulcer gel, its preparation method and application

    CN112426403B

  • Slow-release type oral ulcer hydrogel ulcer patch

    CN114983982A

Cited By

  • Slow-release hydrogel based on oridonin, preparation method of slow-release hydrogel and application of slow-release hydrogel in preparation of auxiliary treatment medicine after melanoma operation

    CN122208514A